Please enable JavaScript to continue using this application.

Compare $GLSI vs $LCTX | Chartloom

Compare

$GLSI vs $LCTX

Greenwich Lifesciences Inc · Lineage Cell Therapeutics Inc

GLSI

Greenwich Lifesciences Inc

LCTX

Lineage Cell Therapeutics Inc

Compare $GLSI vs $LCTX

Comparing Greenwich Lifesciences Inc and Lineage Cell Therapeutics Inc

GLSIGreenwich Lifesciences Inc

LCTXLineage Cell Therapeutics Inc

GLSIGreenwich Lifesciences Inc

Market cap

$243M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-15.1%

52W performance

44.4%

FCF yield

-5.1%

LCTXLineage Cell Therapeutics Inc

Market cap

$248M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

28.49x

Rev growth (TTM)

-37.1%

YTD performance

-39.4%

52W performance

-42.5%

FCF yield

-10.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GLSI

LCTX

Detailed metrics comparison

GLSI

Greenwich Lifesciences Inc

LCTX

Lineage Cell Therapeutics Inc

Market Cap

GLSI$243M

LCTX$248M

Enterprise Value

GLSI$234M

LCTX$210M

Price

GLSI$16.53

LCTX$0.99

P/E Ratio

GLSIN/A

LCTXN/A

P/S Ratio

GLSI0.00x

LCTX18.94x

EV/Sales

GLSI0.00x

LCTX16.09x

EV/EBITDA

GLSI0.00x

LCTX0.00x

P/B Ratio

GLSI79.96x

LCTX3.86x

P/FCF Ratio

GLSIN/A

LCTXN/A

EV/FCF

GLSI-18.72x

LCTX-8.48x

PEG Ratio

GLSIN/A

LCTXN/A

Forward P/E (NTM)

GLSIN/A

LCTXN/A

Forward P/S (NTM)

GLSIN/A

LCTX28.49x

Revenue (TTM)

GLSI$0

LCTX$13M

Revenue Growth (YoY)

GLSIN/A

LCTX-37.1%

Forward Rev Growth

GLSI0.0%

LCTX-16.6%

Gross Margin (TTM)

GLSI0.0%

LCTX94.1%

Operating Margin (TTM)

GLSI0.0%

LCTX0.0%

EBITDA Margin (TTM)

GLSI0.0%

LCTX-199.6%

Net Margin (TTM)

GLSI0.0%

LCTX-246.6%

FCF Margin (TTM)

GLSIN/A

LCTX-189.7%

Net Income (TTM)

GLSI$-22M

LCTX$-32M

FCF (TTM)

GLSI$-12M

LCTX$-25M

EPS (TTM)

GLSI-$1.48

LCTX-$0.13

ROE (TTM)

GLSI-79376.0%

LCTX-7114.0%

ROA (TTM)

GLSI-29531.0%

LCTX-3087.0%

ROIC (TTM)

GLSI-79376.0%

LCTX-7104.0%

Cash

GLSI$9M

LCTX$37M

Debt

GLSI$0

LCTX$48K

Net Cash/Debt

GLSI$9M

LCTX$37M

Current Ratio (TTM)

GLSI1.54x

LCTX6.61x

Quick Ratio (TTM)

GLSI1.54x

LCTX6.44x

Debt/Equity (TTM)

GLSI0.00x

LCTX0.00x

Debt/Assets (TTM)

GLSI0.0%

LCTX0.0%

Interest Coverage (TTM)

GLSIN/A

LCTXN/A

Net Debt/EBITDA (TTM)

GLSI0.00x

LCTX0.00x

Beta

GLSI1.54

LCTX1.67

52W Performance

GLSI44.4%

LCTX-42.5%

YTD Performance

GLSI-15.1%

LCTX-39.4%

% from 52W High

GLSI-51.5%

LCTX-52.4%

% from 52W Low

GLSI112.5%

LCTX12.7%

Asset Turnover (TTM)

GLSI0.00x

LCTX0.07x

FCF Yield (TTM)

GLSI-5.1%

LCTX-10.0%

Earnings Yield (TTM)

GLSI-8.9%

LCTX-13.0%

Dividend Yield (TTM)

GLSIN/A

LCTXN/A

Rule of 40

GLSI0.0

LCTX-226.8

EV/GP/RG

GLSIN/A

LCTXN/A

Ticker research

View GLSI research View LCTX research

Metric	GLSI Greenwich Lifesciences Inc	LCTX Lineage Cell Therapeutics Inc
Market & Valuation
Market Cap	$243M	$248M
Enterprise Value	$234M	$210M
Price	$16.53	$0.99
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	18.94x
EV/Sales	0.00x	16.09x
EV/EBITDA	0.00x	0.00x
P/B Ratio	79.96x	3.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-18.72x	-8.48x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	28.49x
Revenue & Growth
Revenue (TTM)	$0	$13M
Revenue Growth (YoY)	N/A	-37.1%
Forward Rev Growth	0.0%	-16.6%
Profitability
Gross Margin (TTM)	0.0%	94.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-199.6%
Net Margin (TTM)	0.0%	-246.6%
FCF Margin (TTM)	N/A	-189.7%
Net Income (TTM)	$-22M	$-32M
FCF (TTM)	$-12M	$-25M
EPS (TTM)	-$1.48	-$0.13
ROE (TTM)	-79376.0%	-7114.0%
ROA (TTM)	-29531.0%	-3087.0%
ROIC (TTM)	-79376.0%	-7104.0%
Financial Health
Cash	$9M	$37M
Debt	$0	$48K
Net Cash/Debt	$9M	$37M
Current Ratio (TTM)	1.54x	6.61x
Quick Ratio (TTM)	1.54x	6.44x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.54	1.67
52W Performance	44.4%	-42.5%
YTD Performance	-15.1%	-39.4%
% from 52W High	-51.5%	-52.4%
% from 52W Low	112.5%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.07x
FCF Yield (TTM)	-5.1%	-10.0%
Earnings Yield (TTM)	-8.9%	-13.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-226.8
EV/GP/RG	N/A	N/A
Ticker research	View GLSI research	View LCTX research

Valuation

P/S Ratio

GLSI

0.00x

LCTX

18.94x

EV/FCF

GLSI

-18.72x

LCTX

-8.48x

Growth & revenue

Revenue Growth TTM

LCTX

-37.1%

Forward Revenue Growth

GLSI

0.0%

LCTX

-16.6%

Profitability & performance

Gross Margin

LCTX

94.1%

GLSI

0.0%

ROE

LCTX

-7114.0%

GLSI

-79376.0%

FCF Yield %

GLSI

-5.1%

LCTX

-10.0%

52-Week Performance

GLSI

44.4%

LCTX

-42.5%

Detailed metrics comparison

GLSI

Greenwich Lifesciences Inc

LCTX

Lineage Cell Therapeutics Inc

Market Cap

GLSI$243M

LCTX$248M

Enterprise Value

GLSI$234M

LCTX$210M

Price

GLSI$16.53

LCTX$0.99

P/E Ratio

GLSIN/A

LCTXN/A

P/S Ratio

GLSI0.00x

LCTX18.94x

EV/Sales

GLSI0.00x

LCTX16.09x

EV/EBITDA

GLSI0.00x

LCTX0.00x

P/B Ratio

GLSI79.96x

LCTX3.86x

P/FCF Ratio

GLSIN/A

LCTXN/A

EV/FCF

GLSI-18.72x

LCTX-8.48x

PEG Ratio

GLSIN/A

LCTXN/A

Forward P/E (NTM)

GLSIN/A

LCTXN/A

Forward P/S (NTM)

GLSIN/A

LCTX28.49x

Revenue (TTM)

GLSI$0

LCTX$13M

Revenue Growth (YoY)

GLSIN/A

LCTX-37.1%

Forward Rev Growth

GLSI0.0%

LCTX-16.6%

Gross Margin (TTM)

GLSI0.0%

LCTX94.1%

Operating Margin (TTM)

GLSI0.0%

LCTX0.0%

EBITDA Margin (TTM)

GLSI0.0%

LCTX-199.6%

Net Margin (TTM)

GLSI0.0%

LCTX-246.6%

FCF Margin (TTM)

GLSIN/A

LCTX-189.7%

Net Income (TTM)

GLSI$-22M

LCTX$-32M

FCF (TTM)

GLSI$-12M

LCTX$-25M

EPS (TTM)

GLSI-$1.48

LCTX-$0.13

ROE (TTM)

GLSI-79376.0%

LCTX-7114.0%

ROA (TTM)

GLSI-29531.0%

LCTX-3087.0%

ROIC (TTM)

GLSI-79376.0%

LCTX-7104.0%

Cash

GLSI$9M

LCTX$37M

Debt

GLSI$0

LCTX$48K

Net Cash/Debt

GLSI$9M

LCTX$37M

Current Ratio (TTM)

GLSI1.54x

LCTX6.61x

Quick Ratio (TTM)

GLSI1.54x

LCTX6.44x

Debt/Equity (TTM)

GLSI0.00x

LCTX0.00x

Debt/Assets (TTM)

GLSI0.0%

LCTX0.0%

Interest Coverage (TTM)

GLSIN/A

LCTXN/A

Net Debt/EBITDA (TTM)

GLSI0.00x

LCTX0.00x

Beta

GLSI1.54

LCTX1.67

52W Performance

GLSI44.4%

LCTX-42.5%

YTD Performance

GLSI-15.1%

LCTX-39.4%

% from 52W High

GLSI-51.5%

LCTX-52.4%

% from 52W Low

GLSI112.5%

LCTX12.7%

Asset Turnover (TTM)

GLSI0.00x

LCTX0.07x

FCF Yield (TTM)

GLSI-5.1%

LCTX-10.0%

Earnings Yield (TTM)

GLSI-8.9%

LCTX-13.0%

Dividend Yield (TTM)

GLSIN/A

LCTXN/A

Rule of 40

GLSI0.0

LCTX-226.8

EV/GP/RG

GLSIN/A

LCTXN/A

Ticker research

View GLSI research View LCTX research

Metric	GLSI Greenwich Lifesciences Inc	LCTX Lineage Cell Therapeutics Inc
Market & Valuation
Market Cap	$243M	$248M
Enterprise Value	$234M	$210M
Price	$16.53	$0.99
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	18.94x
EV/Sales	0.00x	16.09x
EV/EBITDA	0.00x	0.00x
P/B Ratio	79.96x	3.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-18.72x	-8.48x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	28.49x
Revenue & Growth
Revenue (TTM)	$0	$13M
Revenue Growth (YoY)	N/A	-37.1%
Forward Rev Growth	0.0%	-16.6%
Profitability
Gross Margin (TTM)	0.0%	94.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-199.6%
Net Margin (TTM)	0.0%	-246.6%
FCF Margin (TTM)	N/A	-189.7%
Net Income (TTM)	$-22M	$-32M
FCF (TTM)	$-12M	$-25M
EPS (TTM)	-$1.48	-$0.13
ROE (TTM)	-79376.0%	-7114.0%
ROA (TTM)	-29531.0%	-3087.0%
ROIC (TTM)	-79376.0%	-7104.0%
Financial Health
Cash	$9M	$37M
Debt	$0	$48K
Net Cash/Debt	$9M	$37M
Current Ratio (TTM)	1.54x	6.61x
Quick Ratio (TTM)	1.54x	6.44x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.54	1.67
52W Performance	44.4%	-42.5%
YTD Performance	-15.1%	-39.4%
% from 52W High	-51.5%	-52.4%
% from 52W Low	112.5%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.07x
FCF Yield (TTM)	-5.1%	-10.0%
Earnings Yield (TTM)	-8.9%	-13.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-226.8
EV/GP/RG	N/A	N/A
Ticker research	View GLSI research	View LCTX research